SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19-Reference-Cited by-同舟云学术

SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19

Published:2021-12 Issue: Volume:12 Page:100134
ISSN:2589-9368
Container-title:Metabolism Open
language:en
Short-container-title:Metabolism Open

Author:

Kifle Zemene Demelash^ORCID,Woldeyohanin Alem Endeshaw,Demeke Chilot Abiyu

Publisher

Elsevier BV

Subject

General Medicine

Reference112 articles.

1. DPP4 inhibition: preventing SARS‐CoV‐2 infection and/or progression of COVID‐19?;Strollo;Diabet./Metabol. Res. Rev.,2020

2. B-type natriuretic peptide in cardiovascular disease;de Lemos;Lancet,2003

3. COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy (vol 323, pg 1574, 2020);Grasselli;Jama-J. Am. Med. Assoc.,2021

4. WHO delivers advice and support for older people during COVID-19;Organization,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM);Life Sciences;2024-01

2. Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use;Pharmacy & Pharmacology;2023-04-28

3. DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes;Future Virology;2023-04

4. Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m⁶₂A and CD) regulations on patients with cancer and healthy individuals;International Journal of Oncology;2023-02-16

5. Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control;World Journal of Virology;2022-11-25